NCT04003636 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 533
- group Id
- BG001
- value
- 536
- group Id
- BG002
- value
- 1069
- units
- Participants
- groups
- description
- Participants received pembrolizumab, 200 mg intravenous (IV) infusion, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m\^2, IV infusion Q3W, Day 1 and Day 8 of each 3-week cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m\^2 IV infusion, Q3W, Day 1 and Day 8 of each 3-week cycle for up to 8 cycles. Eligible participants who stopped the initial course of pembrolizumab with Stable Disease (SD) or better but progressed after discontinuation initiated a second course of pembrolizumab 200mg IV Q3W, Day 1 of each 3-week cycle for up to 17 cycles. Treatment with Gemcitabine could have been stopped at any time in first or second course due to toxicity or disease progression.
- id
- BG000
- title
- Arm A: Pembrolizumab + Chemotherapy
- description
- Participants received Placebo to Pembrolizumab, 200 mg IV infusion, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m\^2 IV infusion, Q3W, Day 1 and Day 8 of each 3-week cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m\^2 IV infusion, Q3W, Day 1 and Day 8 of each 3-week cycle for up to 8 cycles.
- id
- BG001
- title
- Arm B: Placebo + Chemotherapy
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.3
- value
- 63.3
- group Id
- BG001
- spread
- 11.0
- value
- 61.8
- group Id
- BG002
- spread
- 10.7
- value
- 62.5
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 253
- group Id
- BG001
- value
- 264
- group Id
- BG002
- value
- 517
- title
- Female
- measurements
- group Id
- BG000
- value
- 280
- group Id
- BG001
- value
- 272
- group Id
- BG002
- value
- 552
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 59
- group Id
- BG001
- value
- 52
- group Id
- BG002
- value
- 111
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 433
- group Id
- BG001
- value
- 449
- group Id
- BG002
- value
- 882
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 41
- group Id
- BG001
- value
- 35
- group Id
- BG002
- value
- 76
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 245
- group Id
- BG001
- value
- 250
- group Id
- BG002
- value
- 495
- title
- Asian
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 14
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 256
- group Id
- BG001
- value
- 268
- group Id
- BG002
- value
- 524
- title
- White
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 7
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 25
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 242
- group Id
- BG001
- value
- 244
- group Id
- BG002
- value
- 486
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 291
- group Id
- BG001
- value
- 292
- group Id
- BG002
- value
- 583
- title
- Non-Asian
- description
- Randomization of participants was stratified by geographic region of the enrolling site (Asia or non-Asia).
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Geographic Region
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 60
- group Id
- BG001
- value
- 66
- group Id
- BG002
- value
- 126
- title
- Locally Advanced
- categories
- measurements
- group Id
- BG000
- value
- 473
- group Id
- BG001
- value
- 470
- group Id
- BG002
- value
- 943
- title
- Metastatic
- description
- Randomization of participants was stratified by disease status as locally advanced or metastatic.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Disease Status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 115
- group Id
- BG001
- value
- 118
- group Id
- BG002
- value
- 233
- title
- Gallbladder
- categories
- measurements
- group Id
- BG000
- value
- 320
- group Id
- BG001
- value
- 313
- group Id
- BG002
- value
- 633
- title
- Intrahepatic
- categories
- measurements
- group Id
- BG000
- value
- 98
- group Id
- BG001
- value
- 105
- group Id
- BG002
- value
- 203
- title
- Extrahepatic
- description
- Randomization of participants was stratified by location of tumor as gallbladder or intrahepatic or extrahepatic bile duct cancers.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Site of Origin
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 533
- group Id
- BG001
- value
- 536
- group Id
- BG002
- value
- 1069
- units
- Participants
- groups
- description
- Participants received pembrolizumab, 200 mg intravenous (IV) infusion, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m\^2, IV infusion Q3W, Day 1 and Day 8 of each 3-week cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m\^2 IV infusion, Q3W, Day 1 and Day 8 of each 3-week cycle for up to 8 cycles. Eligible participants who stopped the initial course of pembrolizumab with Stable Disease (SD) or better but progressed after discontinuation initiated a second course of pembrolizumab 200mg IV Q3W, Day 1 of each 3-week cycle for up to 17 cycles. Treatment with Gemcitabine could have been stopped at any time in first or second course due to toxicity or disease progression.
- id
- BG000
- title
- Arm A: Pembrolizumab + Chemotherapy
- description
- Participants received Placebo to Pembrolizumab, 200 mg IV infusion, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m\^2 IV infusion, Q3W, Day 1 and Day 8 of each 3-week cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m\^2 IV infusion, Q3W, Day 1 and Day 8 of each 3-week cycle for up to 8 cycles.
- id
- BG001
- title
- Arm B: Placebo + Chemotherapy
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.3
- value
- 63.3
- group Id
- BG001
- spread
- 11.0
- value
- 61.8
- group Id
- BG002
- spread
- 10.7
- value
- 62.5
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 253
- group Id
- BG001
- value
- 264
- group Id
- BG002
- value
- 517
- title
- Female
- measurements
- group Id
- BG000
- value
- 280
- group Id
- BG001
- value
- 272
- group Id
- BG002
- value
- 552
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 59
- group Id
- BG001
- value
- 52
- group Id
- BG002
- value
- 111
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 433
- group Id
- BG001
- value
- 449
- group Id
- BG002
- value
- 882
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 41
- group Id
- BG001
- value
- 35
- group Id
- BG002
- value
- 76
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 245
- group Id
- BG001
- value
- 250
- group Id
- BG002
- value
- 495
- title
- Asian
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 14
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 256
- group Id
- BG001
- value
- 268
- group Id
- BG002
- value
- 524
- title
- White
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 7
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 25
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 242
- group Id
- BG001
- value
- 244
- group Id
- BG002
- value
- 486
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 291
- group Id
- BG001
- value
- 292
- group Id
- BG002
- value
- 583
- title
- Non-Asian
- description
- Randomization of participants was stratified by geographic region of the enrolling site (Asia or non-Asia).
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Geographic Region
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 60
- group Id
- BG001
- value
- 66
- group Id
- BG002
- value
- 126
- title
- Locally Advanced
- categories
- measurements
- group Id
- BG000
- value
- 473
- group Id
- BG001
- value
- 470
- group Id
- BG002
- value
- 943
- title
- Metastatic
- description
- Randomization of participants was stratified by disease status as locally advanced or metastatic.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Disease Status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 115
- group Id
- BG001
- value
- 118
- group Id
- BG002
- value
- 233
- title
- Gallbladder
- categories
- measurements
- group Id
- BG000
- value
- 320
- group Id
- BG001
- value
- 313
- group Id
- BG002
- value
- 633
- title
- Intrahepatic
- categories
- measurements
- group Id
- BG000
- value
- 98
- group Id
- BG001
- value
- 105
- group Id
- BG002
- value
- 203
- title
- Extrahepatic
- description
- Randomization of participants was stratified by location of tumor as gallbladder or intrahepatic or extrahepatic bile duct cancers.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Site of Origin
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle